September 20, 2016
David A. Sullivan, PhD, in collaboration with colleagues from several institutions worldwide, evaluated the use of recombinant human lubricin – a glycoprotein with lubricating, anti-adhesive and anti-inflammatory activities – as a treatment for patients with dry eye disease. The results of this clinical trial, published in the September issue of The Ocular Surface, showed significant improvement in signs and symptoms of dry eye disease, without adverse events during the investigation. Current treatments for dry eye disease provide only limited symptomatic relief, so the results of this trial are encouraging as a potential treatment for both measured symptoms and objective signs of dry eye disease.